NEW HAVEN, CT - SEPTEMBER 13, 2019 — Valisure discovered the link of Zantac and its generics to the carcinogen NDMA during its routine testing of every batch of every medication, and first notified the FDA of its initial findings in June of 2019.  On September 13th, Valisure filed a detailed petition with the Food and Drug Administration asking the agency to recall all products containing ranitidine. Valisure’s research, along with that of Stanford University and others, found that NDMA was the result of the “inherent instability” of the ranitidine molecule. This means that all manufacturers, brands or generic, and all lots of ranitidine-containing medications are affected and could generate very high levels of NDMA in the human body.

“There’s no acceptable cancer risk for a drug like this.” –David Light, CEO of Valisure

Valisure’s FDA Citizen Petition: Click here for full Citizens Petition.

‍